Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

438 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Pao W, et al. Among authors: miller va. PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073. Epub 2005 Feb 22. PLoS Med. 2005. PMID: 15737014 Free PMC article.
Trastuzumab in the treatment of non-small cell lung cancer.
Azzoli CG, Krug LM, Miller VA, Kris MG, Mass R. Azzoli CG, et al. Among authors: miller va. Semin Oncol. 2002 Feb;29(1 Suppl 4):59-65. doi: 10.1053/sonc.2002.31526. Semin Oncol. 2002. PMID: 11894015 Review.
The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease.
Laurie SA, Kris MG, Portlock CS, Rosenzweig KE, Miller VA, Krug LM, Rusch VW. Laurie SA, et al. Among authors: miller va. Cancer. 2002 Jul 1;95(1):119-26. doi: 10.1002/cncr.10628. Cancer. 2002. PMID: 12115325
A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.
Downey RJ, Ng KK, Kris MG, Bains MS, Miller VA, Heelan R, Bilsky M, Ginsberg R, Rusch VW. Downey RJ, et al. Among authors: miller va. Lung Cancer. 2002 Nov;38(2):193-7. doi: 10.1016/s0169-5002(02)00183-6. Lung Cancer. 2002. PMID: 12399132 Clinical Trial.
Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.
Ebright MI, Zakowski MF, Martin J, Venkatraman ES, Miller VA, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW. Ebright MI, et al. Among authors: miller va. Ann Thorac Surg. 2002 Nov;74(5):1640-6; discussion 1646-7. doi: 10.1016/s0003-4975(02)03897-3. Ann Thorac Surg. 2002. PMID: 12440623
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
Krug LM, Miller VA, Filippa DA, Venkatraman E, Ng KK, Kris MG. Krug LM, et al. Among authors: miller va. Lung Cancer. 2003 Feb;39(2):139-43. doi: 10.1016/s0169-5002(02)00443-9. Lung Cancer. 2003. PMID: 12581565 Clinical Trial.
Targeting lethal minimal residual disease in small cell lung cancer.
Patel JD, Krug LM, Azzoli CG, Gomez J, Kris MG, Miller VA. Patel JD, et al. Among authors: miller va. Semin Oncol. 2003 Feb;30(1):79-85. doi: 10.1053/sonc.2003.50018. Semin Oncol. 2003. PMID: 12635092 Review.
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J. Miller VA, et al. J Clin Oncol. 2003 Jun 1;21(11):2094-100. doi: 10.1200/JCO.2003.12.008. J Clin Oncol. 2003. PMID: 12775734 Clinical Trial.
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, Ginsberg MS, Venkatraman E, Tyson L, Pizzo B, Baez V, Ng KK, Sirotnak FM. Krug LM, et al. Among authors: miller va. Clin Cancer Res. 2003 Jun;9(6):2072-8. Clin Cancer Res. 2003. PMID: 12796370 Clinical Trial.
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller VA, Rusch VR, Kris MG, Sirotnak FM. She Y, et al. Among authors: miller va. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3773-8. Clin Cancer Res. 2003. PMID: 14506170
438 results
Jump to page